I. Introduction
===============

Mucormycosis is known as a life-threatening fungal disease that destroys hard and soft tissue especially within various predisposing underlying conditions. Among five subtypes (rhinocerebral, pulmonary, intestinal, cutaneous, and disseminated), rhinocerebral mucormycosis (RCM) is a rare, fatal, opportunistic subtype invading the oral and maxillofacial areas including facial sinuses, maxilla, zygoma, orbit, and oral cavity. Clinical signs include facial cellulitis, orbital swelling, black necrotic palate, and facial (VII) and/or trigeminal (V) nerve involvement[@B1]. Nasal obstruction or congestion with noisy breathing, headache, odontalgia, sinusitis with low-grade fever and unilateral facial swelling, maxillary pain, hyposmia, and anosmia have also been described as typical symptoms of the disease[@B2].

This study sought to present a series of cases involving six patients diagnosed with RCM and treated with several methods, consider the prevalence and mortality factors, and analyze each case with reference to related articles.

II. Case Report
===============

Six patients diagnosed with RCM based on tissue biopsy and treated in several conservative and surgical ways in our department between the years 1997-2012 were studied retrospectively. Their clinical symptoms, imaging findings, underlying diseases, surgical methods, and time consumed from the first visit to our department to the first medical and surgical interventions were analyzed and discussed.

The six patients, whose average age was 65.0 years (49-74 years), were diagnosed with mucormycosis in the oral and maxillofacial areas based on tissue biopsy.([Table 1](#T1){ref-type="table"}) Facial swelling (n=3; 50%) and headache (n=3; 50%) were the most common symptoms, followed by hypoesthesia (n=2; 33.3%). Maxillary sinus was involved most frequently (n=5; 83.3%), followed by sphenoid and ethmoid sinus (n=2; 40%) and floor of orbit (n=2; 40%).

Five patients (patient numbers 1, 2, 3, 4, 5) had diabetes mellitus (DM) as an underlying disease (n=5; 83.3%). These patients with DM had surgical intervention and antifungal therapy (amphotericin B \[AmB\] or liposomal amphotericin B \[L-AmB\] or posaconazole); one patient (patient number 6) had polyene gargle treatment only without surgery. Antifungal medication was basically initiated with AmB up to 2.0 g. Monitoring nephrotic values such as level of serum blood urea nitrogen or creatinine and calculating accumulative dose, medications were changed to L-AmB or posaconazole.

Surgical methods were sequestrectomy of the involved maxilla, zygoma, and floor of orbit, ethmoid-sphenoidectomy, Caldwell-Luc operation, and antrostomy. Most of our patients (patient numbers 2, 3, 4, 5) had surgery under the impression of osteomyelitis (OM) as their clinical and radiological aspects. Final reports of the pathologic report enabled us to assure the RCM of four patients 2-7 days after the major surgery. The other patient (patient number 1), as we mentioned above, had final diagnosis of RCM based on tissue biopsy 2 days before he had surgery, i.e., ethmoid-sphenoidectomy. After the surgical intervention, they were referred to the Department of Infectious Diseases at Severance Hospital for intensive antifungal treatment. Before all patients were discharged without any mortality, they had started to be treated in the department of prosthodontics for the restoration of their appearance and function.

We present in detail the case of one patient, a 72-year-old male who had the most aggressive oral-maxillofacial involvement including several facial bones. His had several underlying diseases as seen in [Table 1](#T1){ref-type="table"}. He was first referred to our department with left maxillary gingival pain and suborbital swelling that had started about 10 days before the first visit. The clinical examination revealed generalized swelling and tenderness on the left mid-face with intraoral fistula in the left maxillary vestibule. The facial computed tomography imaging showed extensive invasion of the left maxillary sinus and other facial bones, making extensive sequestrum at the left maxilla, zygoma, nasal bone, floor of orbit, and maxillary alveolar bone.([Fig. 1](#F1){ref-type="fig"}) With OM presumed in the above area, the patient underwent sequestrectomy of the left maxilla, zygoma, alveolar bone, and extraction of the teeth involved. After being diagnosed with RCM based on tissue biopsy ([Fig. 2](#F2){ref-type="fig"}), he was referred to the department of infectious diseases for systemic antifungal treatment, receiving AmB, liposomal amphotericin, and posaconazole. Post-operation wound healing was favorable, and temporary acute renal failure was corrected immediately.

III. Discussion
===============

Early diagnosis, reversal of underlying host impairments, antifungal medication, and surgical intervention are important in treating RCM[@B3].

Clinical/radiological aspects of RCM are not easy to distinguish from ordinary OM in the oral and maxillofacial areas. The clinical symptoms of our patients included atypical pain, swelling, and loss of functions in the oral and maxillofacial areas, and they do not have particular discriminative points such as fungal infection. Moreover, radiological aspects were not beneficial in prognosticating RCM from OM, either. Typical computed tomography (CT) findings include diffuse thickening of the mucosa of the sinuses involved. This is frequently accompanied by the erosion and destruction of the bony sinus wall and extrasinusoidal spread of the infection[@B3]. These resemble the ordinary OM, and the CT views of our patients were also similar to the conventional OM, such as low attenuated irregular intra-bony lesions, sequestrum such as amorphous, high attenuated bony fragments in the affected structure, and increased bony sclerosis in the medullary portion adjacent to the lesions. Because of these unremarkable features of RCM, it used to take time to be aware of fungal infection. When extensive aspect of OM is noted in the oral and maxillofacial areas, we should check the systemic condition and perform prompt tissue biopsy for the confirmation of fungal infection, immediate treatment planning, and proper intervention.

Though the prevalence risk factors and treatment strategies have been well studied for several decades, the rates of mucormycosis with life-threatening mortality are increasing[@B4]. With well-investigated pathophysiologic pathway[@B5],[@B6], DM is the most commonly reported risk factor of mucormycosis particularly in the oral and maxillofacial areas. Roden et al.[@B7] found DM to be the most common underlying condition for mucormycosis in the oral and maxillofacial areas. In the article, diabetes type I and diabetes type 2 were reported as independent predictors for oral and maxillofacial mucormycosis. We could reconfirm the relations between the occurrence of oral and maxillofacial mucormycosis and DM since five of our six patients had DM and unilateral maxillary sinus involvement; two had sphenoid and ethmoid sinus involvement, and two, orbit involvement.

Although an important prevalence risk factor, DM has low relevance with the mortality of mucormycosis[@B7],[@B8]. In contrast, hematologic malignancy is presented as the most fatal factor of mucormycosis in many articles[@B4],[@B7],[@B9]-[@B12]. Given evidence that the prevalence and mortality risk factors of mucormycosis are not the same, we should approach the prevention and treatment of mucormycosis independently. All six patients in our cases survived regardless of whether they had surgical intervention (n=5) or not (n=1). This high survival rate is suggestive, considering other studies reporting high mortality of RCM. Though 83% (n=5) of the patients had DM, all of them were in a course of proper care. We evaluated that no one had hematologic malignancy, which was an important factor for the low mortality in this report.

The efficacy and proper dosage of AmB have been reproducibly demonstrated in both laboratory (*in vitro* and *in vivo*) investigations and in clinical studies[@B12]-[@B16], and there is a report of delayed AmB-based therapy resulting in 2-fold increase in mortality rate[@B12]. The L-AmB formulation has better penetration into cerebral tissue than other agents; hence its potentially better efficacy in cases of rhinocerebral involvement[@B15]. Furthermore, posaconazole, combination therapy with echinocandins and defarasirox, and hyperbaric oxygen can be used as adjunctive therapy in the management of mucormycosis[@B14].

Surgical debridement is fundamental for the successful management of most cases of RCM. Using less aggressive surgical procedures with combined medication may enhance survival from oral and maxillofacial mucormycosis[@B14]. The general impression of intra-operative finding was similar to that of OM as well as clinical/radiological features. There was necrotic bone with sequestrum, with some granulation tissue with pus discharge in the structures involved. Note, however, that there was extensive spreading of the lesions even to the frontal process of maxilla close to the orbit, compared with the OM we used to experience.

We spent 24.6 days and 30.2 days on the average from the first visit to surgical intervention and commencement of antifungal mediation. Despite the difficult diagnosis of RCM, shortening the time to start antifungal medication and surgical intervention were thought to be the most important factors for the high survival rate in our study. The authors performed surgical/medical interventions on oral and maxillofacial mucormycosis patients with variable underlying diseases and reported high survival rate of the cases.
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![A. Preoperation computed tomography (CT) axial view: presenting involvement of left maxilla, zygoma and severe mucosal thickening on both maxillary sinus. B. Preoperation CT axial view: presenting involvement of maxilla, left maxillary sinus; and increased bony sclerosis in the medullary portion of left maxilla. C. Preoperation CT frontal view: presenting involvement of left maxilla, zygoma, floor of orbit, ethmoidal, sphenoidal sinus, nasal cavity, alveolar bone. Arrows indicate the border of the lesion.](jkaoms-39-246-g001){#F1}

![Histological view of rhinocerebral mucormycosis. A. Periodic acid-Schiff (PAS) staining, ×200. B. H&E staining, ×200. C. Grocott\'s methenamine silver (GMS) staining, ×200. Arrows and arrowheads in the figures show aseptate hyphae branching at 90°.](jkaoms-39-246-g002){#F2}
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Summary of rhinocerebral mucormycosis patient data
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(M: male, F: female, DM: diabetes mellitus, MI: myocardial infarction, S/P: status post, PTCA: percutaneous transluminal coronary angioplasty, d/t: due to, CAOD: coronary artery occlusive disease)
